Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2022. The document serves as a transaction notification regarding a specific event involving a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. The only financial data disclosed relates to a specific executive compensation transaction:
- Transaction Type: Cash payment following the vesting of a Deferred Investment Award.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Volume: 29,158.532 notional Ordinary Shares.
- Price: £13.52 per share.
- Total Value: £394,223.35 (gross, before tax withholding).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details the vesting of 25% of an award made on February 14, 2018, to Mr. L Miels, Chief Commercial Officer, on September 4, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of a single transaction event.
Key Facts for Investor Verification
- Verify the identity of the PDMR: Mr. L Miels, Chief Commercial Officer.
- Confirm the transaction date: September 4, 2022.
- Note that the transaction resulted in a cash payment, not the issuance of new shares, based on the vesting of notional shares.
- Understand that this filing does not contain quarterly or annual financial performance data.